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A 4-year-old girl with neurofibromatosis and a one-year history of
hypertension was admitted for repeat renal arteriography and for renal
vein renin determinations. Neurofibromatosis, manifested by café-au-
lait spots, cutaneous neurofibromata, and neurolipomas. had been
diagnosed at age 6 months during evaluation of a large head circumfer-
ence without hydrocephalus. Physical examination and growth and
development were otherwise normal. The family history was negative
for neurofibromatosis and hypertension.
One year prior to admission, her blood pressure was 130—140/90 mm
Hg during a routine checkup; she was asymptomatic at that time.
Laboratory evaluation included normal urinalysis (specific gravity,
1.022; pH, 5.0; no albumin; no blood; no glucose; no ketones; and an
unremarkable sediment). Urine culture showed no growth. Serum
creatinine was 0.4 mg/dl; BUN, 12 mg/dl; sodium, 139 mEq/liter;
potassium, 3.5 mEq/liter; chloride, 103 mEq/liter; carbon dioxide, 24
mmol/liter; calcium, 9.5 mg/dl; phosphate, 4.7 mg/dl; and blood sugar,
108 mgldl. A radionuclide renal scan showed equal function bilaterally,
and an ultrasound examination of her kidneys and suprarenal areas was
normal. A 'spot" VMA and plasma catecholamines also were normal;
peripheral plasma renin activity was 4.0 ng/ml/hour. Renal arteriogra-
phy revealed an ostial stenosis of the left renal artery. Renal vein renin
levels were not obtained.
She was treated with a combination of hydralazine, nifedipine, and
enalapril, but her blood pressure failed to return to normal. Accord-
ingly, elective repair of the ostial stenosis was performed using a left
end-to-side splenorenal artery shunt. Hypertension persisted despite
the apparently satisfactory revascularization procedure. Blood pressure
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was controlled with a combination of enalapril, hydralazine, and
nifedipine. Renal function and plasma catecholamines remained nor-
mal; a cerebral CT scan showed no hydrocephalus.
The patient was admitted to the hospital for further evaluation.
Discussion
DR. JULIE R. INGELFINGER (Co-Director, Pediatric Nephrol-
ogy Unit, Massachusetts General Hospital, and Associate
Professor of Pediatrics, Harvard Medical School, Boston,
Massachusetts): Primary hypertension is diagnosed in children
more and more frequently now that blood pressure norms are
available even for newborns. However, severe hypertension in
a very young child, such as the little girl described here, is still
much more likely to be due to a definable cause of hypertension
than to represent so-called primary hypertension [1]. In the
overall pediatric population [2], renal and renovascular diseases
account for close to 90% of definable hypertension in the first
years of life; the percentage actually might be even higher. For
the current discussion, I will first focus on renovascular disease
in early childhood and present the current knowledge about its
cause, evaluation, and therapy. I will focus on the vascular
changes that produce hypertension and will concentrate less on
changes that result from elevated blood pressure. I then will
discuss the development of the renal vasculature and factors
that might be important in its normal growth and remodeling.
Finally, I will consider briefly the specific abnormalities in the
renal artery vasculature in patients with neurofibromatosis.
Etiology
A variety of diseases can lead to renal and renovascular
hypertension, although only a few arterial lesions are common
in children. In the late l960s and early 1970s, McCormack and
colleagues developed a classification based on the layer of the
vascular wall involved; this classification scheme is the current
framework used to describe renovascular lesions [3, 4]. Table 1
lists the common causes of renovascular hypertension; let me
review these briefly.
The most frequent causes of renovascular hypertension in
childhood are the various lesions that fall into the category
fibromuscular dysplasia [5—7]. Lesions of the intima occasion-
ally are seen [8—13]. The intimal lesion involved consists of a
circumferential, often eccentric, accumulation of loose fibrous
matrix with a moderate number of cells and without inflamma-
tory change or lipid accumulation. Whereas the internal elastic
lamellae sometimes show duplications, more often the lamellae
are intact and normal. For reasons not understood, the findings
in the small percentage of patients with congenital rubella, who
may develop renovascular hypertension, most often fall into
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Table 1. Causes of renovascular hypertension in childhood
Intrinsic lesions
Fibrous and fibromuscular dysplasia
Intima
Intimal fibroplasia
Media
Medial fibroplasia (+1— aneurysms)
Medial hyperplasia
Perimedial fibroplasia
Adventitia
Periarterial fibroplasia
Genetic disorders
NFl (vascular neurofibromatosis)
Williams syndrome
Feuerstein-Mimms syndrome
Klippel-Trenaunay-Weher syndrome
Thromboembolism
Post-umbilical catheter
Post-angiography
Post-trauma
Inflammatory stenoses
Takayasu syndrome
Moyamoya syndrome
Sarcoidosis
Kawasaki syndrome
Aortitis
Atherosclerosis
Progeria
Hyperlipidemias
Post-transplant
Extrinsic lesions
Tumor
Wilms'
Neuroblastoma
Pheochromocytomalganglioneuroma
Lymphoma
Congenital fibrous band
Post-trauma
Hematoma
Retroperitoneal fibrosis
Lymphadenopathy
this category [8]. Intimal lesions also are common in children
with Williams syndrome, also called idiopathic hypercalcemia
of infancy, which is characterized by unusual (leprechaun-like)
facies, developmental retardation, cardiac lesions, and multiple
vascular stenoses [14—16].
Fibromuscular dysplasia involving the media, the most fre-
quent cause of renal artery disease, can occur with or without
aneurysms [4]. The main renal artery, segmental branches, or
both can be involved, with the arterial wall manifesting focal
areas of thickening alternating with very thin areas. Arteriog-
raphy generally reveals a "string of beads" pattern; the media
often is replaced by a collagenous and fibrous matrix and
degenerated elastic fibers that displace and disorient smooth
muscle cells. Elastic lamellae often are deficient in these areas
of media. In patients with fibromuscular disease involving the
media, the longitudinally oriented smooth muscle cells in ad-
ventitial regions appear hypertrophic. In contrast to the fre-
quency of intimal and medial disease, adventitial periarterial
fibroplasia is relatively rare and is characterized by the deposi-
tion of collagen in the adventitia and fibroplasia of the surround-
ing connective tissue [4]. This adventitial lesion is often char-
acterized by chronic inflammation (lymphocytes and plasma
cells) within the connective tissue surrounding the arteries;
small vessels and capillaries also can be cuffed by inflammatory
cells.
Genetic disorders associated with renovascular disease are
fairly common causes of hypertension in children. In the
pediatric population, the most common genetically determined
renovascular disorder is neurofibromatosis (NF), a hereditary
congenital dysplasia of ectodermal and mesodermal tissues
characterized by vascular lesions [17—28]. In fact, a number of
pathologic studies that have reviewed cases of fibromuscular
dysplasia in children have found most of these cases to be in
individuals who have neurofibromatosis. Almost all children
with NF develop vascular lesions, which can occur in virtually
any artery; NF-associated stenosis, however, most commonly
affects the abdominal aorta, and the renal, internal carotid, and
vertebral arteries. Arterial lesions in NF include: (1) pure
intimal lesions; (2) advanced intimal lesions and medial chang-
es; (3) nodular aneurysmal lesions with loss of media elements;
(4) periarterial nodular abnormalities; and (5) epithelioid lesions
with marked cellular proliferation [29]. The most common
lesion in NF consists of fibrous thickening of the intima; small
blood vessels (vasa vasorum) can be seen within the remaining
slit-like lumens. The internal elastic membranes often are
fragmented and duplicated. Nodular collections of cells, seen in
junctional zones between the intima and muscularis, are
thought to represent smooth muscle cells [23] or nodules of
neural origin [29].
Children with other genetically based disorders, such as
Williams syndrome [14-16], Klippel-Trenaunay-Weber syn-
drome [7], and Feuerstein-Mimms syndrome [71, may have
renovascular hypertension. The renal lesions in these patients
appear to be in the category of fibromuscular dysplasia. Patients
with tuberous sclerosis, who often develop intrarenal cystic
lipomatous lesions, occasionally also develop arteriovenous
malformations, which are associated with hypertension [30].
Thromboembolic occlusion of renal vessels is the most com-
mon cause of acute hypertension in premature or ill neonates
[31—35]. In the newborn period, umbilical arterial catheteriza-
tion is the usual prelude to arterial thrombosis. Trauma to
endothelium, platelet aggregation, and subsequent thrombus
formation is the usual sequence of events. Thromboembolic
renal artery lesions occur less frequently in older infants and
children, and the index of suspicion for this diagnosis is
heightened if a history of trauma or catheterization exists;
confirmation of the diagnosis requires angiography. Renal ar-
tery thrombosis occasionally can occur in older children after
angiography [36], but close monitoring and administration of
anticoagulants when the renal vessels are manipulated usually
averts this unfortunate event. Following blunt trauma, as in
motor vehicle accidents, renal vessels can be occluded, and it is
important to bear this possibility in mind.
Inflammatory renal artery stenosis related to a vasculitis,
while rare, does occur in children. Takayasu arteritis [37—39],
Moyamoya syndrome [40], and sarcoidosis [41, 42] all have
been associated with renovascular hypertension. Occasional
reports of renovascular hypertension following Kawasaki dis-
ease also have been published [43]. Arteriosclerosis, also rare in
children, occurs virtually only in syndromes such as progeria or
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the dyslipidemias [44—46]. Renovascular disease has been re-
ported as part of a diffuse arterial calcified elastopathy. The
pathogenesis has not been elucidated [47, 48].
Renal artery stenosis can occur in children who have under-
gone renal transplantation [49]. Post-transplant hypertension
can result from a number of problems other than renovascular
disease, and these disorders must be considered. Acute and
chronic rejection, the presence of multiple kidneys, medication,
hypercalcemia, pyelonephritis, hydronephrosis, and/or recur-
rent nephropathy all are associated with hypertension. The
renal artery itself can be compromised due to intrinsic narrow-
ing related to suture placement, rejection phenomena, neovas-
cular changes, or scarring.
Extrinsic compression can account for post-transplant renal
artery stenosis. This topic has been reviewed recently [49, 50].
Such extrinsic causes of renovascular narrowing can cause
severe, acute hypertension [7, 51—55]. Conditions resulting in
external compression include tumors (Wilms', neuroblastoma,
pheochromocytoma, and lymphomas), congenital bands, and
neurofibromas. Following trauma, hematomas also can com-
press the renal artery.
Clinical manifestations
The clinical manifestations of renovascular hypertension
vary considerably [56—58]. Like the child presented here, how-
ever, most youngsters are asymptomatic. When symptoms
occur, they range from mild to severe and include headaches,
confusion, epistaxis, anorexia, failure to thrive, and those of
heart failure; polyuria, polydipsia, and nocturia (manifestations
of a renal concentrating defect); and Bell's palsy. Because
renovascular hypertension accounts for a substantial number of
definable causes of hypertension but is frequently silent, the
physician must consider it strongly in any hypertensive young-
ster. Thus, young children with severe hypertension without a
positive family history should have a complete evaluation for
renovascular hypertension. Hypertension after trauma, marked
and difficult-to-control hypertension, and hypertension with a
change in renal function all are clinical features associated with
renal artery stenosis and should lead the clinician to perform a
complete renovascular evaluation. Physical examination also
can be invaluable in providing hints as to the presence of
renovascular hypertension. Obviously the features of systemic
diseases such as NF and Williams syndrome must be sought;
detection of an abdominal or flank bruit, especially one that is
diastolic and lateral to the midline, hints at the presence of a
renal artery lesion.
Diagnosis
Diagnostic studies intended to define renal and renovascular
diseases are divided into phases or stages in the pediatric
patient just as in the adult [1, 59]. Initial screening tests should,
at a minimum, include urinalysis, urine culture, measures of
renal function (at least BUN and serum creatinine), serum
electrolytes, and an evaluation of cardiac status by echocardi-
ography or electrocardiogram plus chest radiograph. Next,
studies that raise or lower the index of suspicion about reno-
vascular disease should be carried out. Several suggested tests
include peripheral plasma renin activity (caval and renal vein
sampling are done later), and cardiac and renal imaging [1, 58,
59].
Peripheral plasma renin activity is influenced by a variety of
volume-related and hormonal factors as well as by dietary salt
intake [60]. Many medications also can increase or decrease
plasma renin activity [60]. Thus, it is not surprising that therapy
of hypertensive children can interfere with assessing the plasma
renin activity or concentration accurately. Nonetheless, con-
trolling the patient's elevated blood pressure is of prime impor-
tance and takes precedence over any diagnostic study. A
"random" plasma renin activity value, unless very high or very
low, is not of much help.
I recommend obtaining an initial plasma renin activity value
pnor to the administration of a diuretic or first dose of an
angiotensin-converting-enzyme inhibitor. I interpret the results
of such pre-treatment renin activity on the basis of the normal
renin activity for the age of a child, the norms for the laboratory
being used, and the conditions of sampling [60-64].
Renal vein renin sampling, with or without the patient having
been given a converting enzyme inhibitor, may help in deter-
mining whether vascular stenosis is the physiologic cause of
hypertension [65—67]. Renin activity is determined in blood
samples from the renal veins (or renal vein segments), and from
the inferior vena cava both below and above the renal veins [52,
57]. To show renin dependence, this study should demonstrate
hypersecretion of renin from the suspect region (V1), suppres-
sion from the normal region (V2), and decreased perfusion of
the suspect area as demonstrated by an increased concentration
of renal-vein renin compared to the inferior vena cava concen-
tration (systemic). Thus, the ratios between the affected side
and normal should be at least 1.5:1.0 if one is to predict
improvement in blood pressure control with interventional
radiologic procedures or surgery [66]. Increased renin flowing
from a kidney (or a renal segment) with renovascular lesion(s)
should suppress the renin secretion from the contralateral
normal kidney to a level equal to that in the systemic circulation
(V2 — IVC =
—0); if the normal side is not suppressed, surgical
cure is less likely [66]. Partial nephrectomy based on the results
of a segmental renal vein renin sampling study has been helpful
in curing children with renal artery disease [65].
The utility of renal imaging studies in the hypertensive
pediatric population remains a subject of great debate. The
accuracy of any given imaging method depends not only on the
technique, but also on the experience of the center using that
technique, especially the experience with children [1]. Refine-
ments in ultrasonography [68] and the possible combination of
that technique with Doppler flow [69—72] enables the evaluation
of renal blood flow in more effective ways. The ultrasound
examination gives a good view both of the kidneys and of the
suprarenal areas, although adrenal evaluation is not complete
with ultrasound. Using Doppler renal flow, one can examine the
flow characteristics of the aorta as compared with the distal and
proximal renal artery [72]. In addition, the Doppler probe can
be placed over the cortex of the kidney (localized by ultra-
sound); subsequent wave form analysis indicates the level of
renal blood flow. This technique can be very accurate, ap-
proaching about 90% agreement with the "gold standard,"
arteriography [61]. Furthermore, the addition of a converting
enzyme inhibitor sometimes reduces renal blood flow and
decreases renal function in the kidney with moderate to severe
renal artery stenosis. In such a study, the routine determination
for arterial flow is performed; then 0.3 mg/kg of captopril is
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administered [73]. One hour after administration of the drug,
the studies are repeated. Should renal blood flow decrease
markedly, the patient is likely to have a significant stenosis of
the renal artery [73]. This study has not been performed in large
numbers of children [73]. Conventional ultrasound, in combi-
nation with radionuclide renal scanning, has a high sensitivity
and specificity for finding renal artery disease [67, 73]. Ultra-
sonography should be done as a screening test in any youngster
with persistent hypertension, as ultrasound at least defines
renal location and configuration.
Let me inject a word about the intravenous pyelogram (IVP).
This test permits the detection of asymmetry in renal size,
persistent delay in excretion of radiocontrast material when
there is unilateral renovascular disease, or persistent nephro-
gram on both sides when bilateral renovascular disease is
present. When several films are taken shortly after the injection
of contrast material, the procedure is called a "rapid-sequence"
IVP. Unfortunately, just as in adults, the sensitivity of the
rapid-sequence IVP in hypertensive children is low, at most
65% [74, 75]. When bilateral renovascular disease is present,
this test is even less sensitive. For this reason, an IVP should be
done only when other imaging tests are unavailable.
Computed axial tomography (CT scanning) is a good diag-
nostic test for renal parenchymal abnormalities but is limited in
its ability to detect renovascular disease even when used with
radiocontrast enhancement. Magnetic resonance imaging (MRI)
has the potential to visualize renal vessels using flow-related
angiography [76—78], but such studies are not yet widely avail-
able and are neither sensitive nor specific enough to be recom-
mended for common use in children [36].
Radionuclide renal scans using several rapidly decaying
isotopes—technetium-99m (mTc), iodine-l3l (''I), and io-
dine-l23 ('231)—can be used to document renal flow and cortical
function [79, 80]. So-called renal morphology agents, 99mTc
dimercaptosuccinate (DMSA) and 99mTcglucoheptonate
(99mTCGHA) are used to obtain at least semi-quantitative
estimates of renal function in the absence of obstruction [79,
80]. However, functional agents such as DTPA and '311-or-
thoiodohippurate provide excellent estimates of function [79,
80]. Preferable in the pediatric population, '231-orthoiodohippu-
rate gives a lower radiation dose to kidneys, gonads, and the
whole body [79, 80]. Recently, 99mTcMAG3 (mercaptoacetyl-
triglycine) has been shown to be a superior agent to or-
thoiodohippurate in visualizing renal parenchyma and gives fine
results in children [81]. The use of captopril as an aid to the
renal scintiscan for detecting renovascular hypertension in
children is becoming increasingly popular [82, 83]. Some cen-
ters obtain a pre-captopril renal scan, then administer the agent
and obtain a second scan. Others prefer to get a single scan after
using captopril for variable lengths of time.
The computerized collection, storage, and manipulation of
angiographic data have substantially improved the value of
renal arteriography because the data can be reconfigured in a
number of ways for subsequent analysis following the study
[84—86]. Standard cut film arteriography, digital subtraction
angiography, and digital venous subtraction angiography
(DVSA) all provide images of the renal vessels after contrast
injection. Venous angiography combines central venous injec-
tion with computer-enhanced imaging over the region of inter-
est. Obviously, this technique avoids arterial cannulation and
the complications of direct arteriography. In DVSA, a centrally
placed venous catheter is used to inject a large bolus of contrast
medium into the superior vena cava or right atrium. The
delayed enhanced images are collected over the abdominal
aorta and kidneys, producing an angiogram that represents a
subtraction, or difference, image. This image is formed by
subtracting an unenhanced image prior to the arrival of contrast
material from the enhanced image after the peak arrival of the
bolus of full-strength contrast medium. The sensitivity and
specificity of DVSA have been debated. Motion and artifact can
result in a poor image, which will hinder accurate interpretation
of the study. Because children can have segmental fibromuscu-
lar disease, DVSA often is not sensitive enough for accurate
detection. In an older child, this method is helpful in ruling out
main renal artery disease.
Arterial cannulation is necessary both for digital subtraction
angiography (DSA) and conventional angiography [84—86] if
segmental vessels are to be well visualized. In children less then
5 years old, direct angiography is best performed with general
anesthesia with standard arteriographic technique. The origins
of the renal arteries generally are best visualized with an
oblique (15°) view. Views obscured due to overlapping vessels
can often be improved with DSA, because images can be
reformatted subsequently. Transient vascular spasm can occur
after selective renal cannulation, and it is crucial to distinguish
this phenomenon from fibromuscular disease. To determine
whether an apparent narrowing represents true stenosis or
vascular spasm, one should use either a second injection with
lower volume and pressure, or a central injection.
Therapy
The objective of therapy of renovascular disease is both
preservation of renal function and correction of hypertension.
In the l980s, the development of interventional techniques
averting the need for surgery changed the approach to the
therapy of renovascular disease in children [87, 88].
Many surgical techniques have long been available [73,
89—91]. Traditionally, first-choice surgery in pediatric patients
has been a bypass graft from the aorta to the renal artery distal
to the area of stenosis. In children, vessels are small and
growing; thus autologous tissue, such as the internal iliac
artery, is the preferred conduit. Using an autologous conduit,
subsequent normal vascular growth without aneurysm dilation
is likely. When an autologous artery is not available, a distal
saphenous vein or a splenorenal bypass can provide an effective
graft. Often, autotransplantation of the kidney after bench
repair is successful [73]. Nephrectomy should be avoided
whenever possible [56—58, 73, 89—91].
Transluminal angioplasty (TLA) has been used extensively in
the therapy of atherosclerotic renal artery disease in adults
[92—95]. The procedure recently has gained popularity in adults
for the treatment of fibromuscular renal artery disease [92—95],
and TLA has been used over the last decade in increasing
numbers of children with renovascular disease [87, 96-104].
Renal artery stenosis in a transplanted kidney also is amenable
to balloon dilation [87, 105]. Now that balloons of more resilient
materials are available, the technical procedure is more effec-
tive. In performing TLA it is important that one select a balloon
catheter that will slightly overstretch the stenotic segment.
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Many children have bilateral disease, and in such circum-
stances it is best to manipulate one side at a time to avoid the
possible complication of bilateral thrombosis.
Hypertension usually improves after TLA. However, about
one-third of patients develop a subsequent stenosis. Various
series have reported disparate results. The success of TLA
depends on the location of the renal artery disease; the most
successful results generally are achieved with short stenotic
lesions [871. Lesions at the origin of the renal artery, or lesions
in which long segments of the renal artery are stenosed (often
seen in neurofibromatosis) are particularly refractory to dilation
[98]. A review of several reports comparing small numbers of
pediatric patients treated with TLA suggests that this technique
should be used when the arterial lesion is in a favorable location
[105]. Long-term followup is not yet available, nor has a
standardized approach to prevention of clot formation following
the procedure emerged.
The successful use of intravascular stents or baffles for
correcting renal artery stenosis has now been reported in adults
[106]. The use of such devices in children is still theoretical.
Stints remain in situ permanently after their placement, so it is
important that the stint be of the caliber ultimately expected for
the fully developed renal vessel.
Transcatheter ablation of renal tissue has been suggested for
some forms of renal hypertension not easily treated with
surgery or transluminal angioplasty [107—110]. For instance, a
segmental artery stenosis that cannot be dilated or resected
might be approached by selective infarction. A variety of agents
have been utilized for renal ablation including gelfoam sponge,
polyvinyl alcohol, ethanol, stainless steel minicoils, and autol-
gous clot. A co-axial catheter system is used for placement of
the ablating material. The important procedural concerns are
the prevention of larger embolization than planned, the avoid-
ince of infection, and the control of post-procedural pain,
which can be severe. As experience is limited in the pediatric
population, medical ablation should be used only in children
who are very poor risks for other procedures.
Pharmacotherapy in children with hypertension follows the
same basic principles as that in adults, that is, monotherapy
should be used when possible and other agents added stepwise
is needed [111—117]. Pharmacologic therapy of children with
severe hypertension due to renovascular disease is now far
simpler with the availability of many new, potent, and more
specific medications. However, most newer drugs are not
:ested specifically in young children, and the caveat, "safety
md efficacy in children is not known," generally appears in the
-nanufacturer's literature. Particular concerns in the pediatric
atient include unique aspects of pharmacokinetics, untoward
side effects, and drug toxicity. The pharmacokinetics of hypo-
;ensive agents may be different in children compared to adults.
For example, the half-life of renally excreted agents is longer in
nfants, in whom glomerular filtration rate is relatively de-
reased. Substantial experience has been documented in chil-
Iren in the use of angiotensin converting enzyme (ACE) inhib-
tors, calcium antagonists, newer beta blockers, and the
ombined alpha/beta blocker labetalol, yet none of these agents
s formally approved for use in children. The doses used
enerally are obtained by scaling down the adult doses and
;tarting at a minimal dose, as shown in Table 2. Specific
)roblems in treating children with renovascular disease include
a decrease in renal function with potent agents such as ACE
inhibitors and the need for polypharmacy in severe hyperten-
sion.
Development and remodeling of renal and intrarenal arteries
Before closing by briefly commenting on the abnormal vas-
culature in neurofibromatosis, let me review the growth and
development of the renal vasculature. The morphology of the
renal vasculature in the human follows a set pattern in the
maturing metanephros, well described in Jean Oliver's land-
mark tome published nearly 25 years ago [118]. After the
ureteral bud first divides, arteries from the aorta and veins from
the vena cava are visible next to the primitive ureter. These
vessels give rise to branches traversing the metanephric blas-
tema, which surrounds the ampullae. The terminal branches of
these newly formed arteries and veins extend to the periphery
and there anastomose into a subcapsular network. By 14 or 15
weeks of intrauterine life, the vascular pattern of the fetal
kidney resembles that of the mature kidney. At this time,
branches of arteries near the future corticomedullary junction
start to elongate parallel to this zone, becoming arcuate arter-
ies. When development is complete, the glomeruli in the outer
to 3/4 of the cortex will be supplied by branches of the
interlobular arteries; the juxtamedullary glomeruli are supplied
directly by branches of the arcuate, oblique, or interlobular
vessels. Although this architectural blueprint is known, the
factors that specifically lead to normal or abnormal renovascu-
lar development are understood far less well. What is known
about vascular development, however, together with some
lessons concerning renal vascular development in abnormal
states, permits us to make several statements concerning reno-
vascular disease in children.
Angiogenesis is a major part of embryogenesis. During de-
velopment, cells in the vasculature organize into layers, each
derived from mesenchyme. These are the tunica intima, made
up of endothelial and smooth muscle cells; the tunica media,
made up of multiple layers of smooth muscle cells; and the
tunica adventitia, made up of loose connective tissue containing
small vessels and nerves. All blood vessels, even capillaries,
have a lining of polarized endothelial cells. The luminal surface
of these cells has nonthrombogenic properties; the antiluminal
surface produces basement membrane substances. Other cell
types that are part of the vessel wall—pericytes, smooth muscle
cells and adventitial fibroblasts—are recruited during vascular
development, in large part by signaling from the endothelial
cells.
Two disparate mechanisms appear to be involved in the
growth of the vasculature during embryonic development.
First, blood vessels develop from endothelial cells of blood
islands that differentiate in situ, a process referred to as
vasculogenesis [119]. Vasculogenesis is distinguished from an-
giogenesis, or the sprouting of capillaries from existing vessels.
The initial step in the development of the vascular system is the
induction of so-called blood islands, or hemangioblasts; this
step seems to require endoderm-mesoderm interaction. Vascu-
logenesis is the process by which blood vessels develop from
differentiating endothelial cells from the blood islands. A vari-
ety of factors, "angiogenesis factors," appear to be important
in the embryonic development of blood vessels. Such factors
include acidic and basic FGF, TGF-a, TGF-/3, TNF, adipocyte
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Table 2. Medications for treatment of chronic hypertensiona
Drug Initial daily dose
Maximum daily
dose Frequency Available formulation
Diuretics
Hydrochlorothiazide 1.0 mg/kg (60 mg/rn2)
3.0 mg/kg (<6 mo of age)
100 mg
37.5 mg
bid
bid
50 mg/S ml solution
25, 50, 100 mg tablets
Chlorotbiazide 20 mg/kg (600 mg/m2)
30 mg/kg (<6 mo of age)
1000 mg
375 mg (up to 2 yrs)
bid
bid
250 mg/5 ml solutions
250, 500 mg tablets
Furosemide 1—2 mg/kg 320 mg or 4 mg/kg bid, qd 40 mg/S ml, 10 mg/mI
solutions; 20, 40, 80 mg
tablets
-Adrenergic antagonists
Nonselective
Propranolol 1—2 mg/kg 8 mg/kg bid 20 mg/S ml solution 10, 20,
Nadolol 40 mg" 640 mg qd
40, 60, 80 mg tablets
20, 40, 80, 120 mg tablets
Selective
Atenolol 50 mg" 100 mg qd 25, 50, 100 mg tablets
Metoprolol
Acebutolol
100—200 mg"
200—400 mg"
450 mg
1200 mg
qd, bid
qd
50, 100 mg tablets
200, 400 mg tablets
Complex adrenergic
antagonists
Labetalol 50—100 mg'' 1200—2400 mg bid 100, 200, 300 mg tablets
Central sympatholytics
10 mg/kg (300 mg/rn2) 65 mg/kg (2g/m2) bid, tid, qid 250 mg/S ml solution, 125,
250, 500 mg tablets
Alpha methyldopa
Clonidine 0.05—0.1 mg tablet
0.1 mg/day patch
2.4mg by mouth
0.6mg by patch
bid, tid
q week
0.1, 0.2, 0.3 mg tablets
0.1, 0.2, 0.3 mg patches
Guanabenz 0.08—0.2 mg/kg (>12 yrs) 64 mg bid 4, 8 mg tablets
Direct vasodilators
Hydralazine 0.5—1.0 mg/kg (25 mg/rn2) 4—8 mg/kg (200 mg) tid, qid 10, 25, 50 mg tablets
Minoxidil 0.1 mg/kg 1 mg/kg (50 mg) bid, qd 2.5, 10mg tablets
Calcium-channel blockers
0.25 mg/kg 1—2 mg/kg (180 mg) tid, qid 10, 20 mg capsulesNifedipine
Extended release
Diltiazem 60—120 mgb
1—2 mg/kg (90 mg)
360 mg
qd
bid, qd
30, 60, 90 mg tablets
60, 90, 120 mg tablets
Verapamil 120—240 mg" 480 mg bid, qd 120, 240 mg tablets
Peripheral alpha blockade
1—2 mg 20 mg bid, tid 1, 2, 5 mg tabletsPrazosin
Angiotensin-converting-enzyme
inhibitors
Captopril
Enalapril
Lisinopril
0.05—0.1 mg/kg
1.25—2.5 mgb
2.5 mg"
4mg/kg (200mg)
40mg
20 mg
bid, tid
bid, qd
bid, qd
12.5, 25, 50, 100mg tablets
2.5, 5, 10, 20mg tablets
5, 10, 20, 40 mg tablets
a Adapted from Jung FF and Ingelfinger JR, Hypertension in Childhood and Adolescence, Pediatrics in Review, Boston, Blackwell Scientific
Publications, Inc.
b Pediatric dose is not established. This table is not an exhaustive list, but it is intended as a reference of most drugs currently used.
lipids, angiogenin, and various prostaglandins [119—123]. These
factors affect endothelial cell proliferation and motility. The
subsequent development of larger vessels involves endothelial
cell secretion of chemotactic factors, as well as mechanical
factors present as embryonic blood circulates [119—1231. Fetal
blood vessels are surrounded by a vascular extracellular matrix
that contains much fibronectin and laminin. Factors that form
the renal vasculature in utero are incompletely understood.
However, studies of microvasculature suggest that cells at the
distal tip of an angiogenic "sprout" express features both of
endothelial and smooth muscle cells, while endothelial cells
more proximal to the "potential" vessel show a more charac-
teristic "endothelial" phenotype. The extracellular matrix
modulates microvascular migration in culture. For instance,
TGF-/3 reduces mesangial cell migration; this migration is
increased by laminin, fibronectin, and types I, IV, and V
collagen [120, 1211,
The direction of blood flow in the developing vasculature
appears to change direction several times. The development of
larger vessels in the embryo is thought to be influenced not only
by the secretion of chemotactic factors, which attract cells to
the vascular wall, but by physical forces and mechanical
stresses imposed by blood flow in the fetus [119].
Some evidence indicates that the number of smooth muscle
layers in larger arteries is predetermined and already present at
birth [1241. Subsequent medial thickening, then, is due to
increased production of connective tissue, cell mass, or cell
number—not to the number of cell layers. There are differences
in the vascular development of spontaneously hypertensive rat
embryos as compared with vascular growth in normotensive
rats [125, 126]. Evidence suggests that while endothelial cell
migrate into developing anlage, smooth muscle cells are locally
derived [1221. Schwartz et a! have suggested that implicit in this
concept is the possibility that smooth muscle cells within the
vasculature can have different origins, depending both on their
location within organs and tissues and on signaling factors that
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can attract them during vascular development [1221. Possibly,
various growth factors of the endothelium act both by modu-
lating the matrix and thus cell-to-substrate interactions within
vessels and by modulating cell-to-cell interactions. Such a
concept allows for the possibility that there exists a common
action for growth factors as morphogens and as mitogens. It is
interesting to speculate that the changes in the vasculature seen
in certain inherited systemic diseases associated with renovas-
cular hypertension such as vascular NF-l or Williams syn-
drome may be influenced by changes in endothelial cell signal-
ing resulting in pathogenic cell:matrix or cell:cell interaction.
We can also hypothesize a similar pathogenesis for acquired
renovascular lesions.
In the kidney, certain vasoactive substances affect the vas-
culature. The developmental expression of one of these sub-
stances, renin, is different in the fetus from that in the mature
organism [127, 128]. In the case of renin, there is a far wider
expression of both its mRNA and protein in the fetal vascula-
ture. In the fetus, renin-producing cells are found in large
amounts in the afferent and efferent arteriole, and the expres-
sion regresses with development [129]. Animals transgenic for
the renin promoter attached to the large T antigen of the SV4O
virus develop a pathologic vasculature [130]. Other animals
transgenic for other aspects of the renin-angiotensin system
also have an aberrant renovascular development [131].
Let's return to today's patient. The repeat arteriogram re-
vealed bilateral renal artery stenosis and stenosis of a branch of
the right renal artery, as well as superior mesenteric artery
stenosis. Thus, her vasculopathy was progressive. How might
the vasculature in neurofibromatosis, as seen in this little girl,
have become abnormal? This child has probable neurofibroma-
tosis type 1 (NF—l), for which the gene (a transcript encoding 13
kilobases) was recently isolated using positional cloning [132,
133]. Several point mutations and deletions have been de-
scribed in this gene on the long arm of chromosome 17. The
presumed NF—l gene product appears to be a polypeptide of
2818 amino acids, a GAP (guanosine triphosphatase [GTP]-
activating protein) that controls or is controlled by the ras
oncogene [134—136]. The ras oncogene is important in growth,
and an abnormality in its control obviously could affect growth,
development, and differentiation, Indeed, in the human, the ras
gene products appear to function as coupling proteins between
mitogen receptors and effector molecules [121]. It is intriguing
to speculate that the underlying defect in NF—l results in a
long-term potential for abnormal vascular development and
remodeling, ultimately culminating in renal arterial disease and
hypertension.
Questions and answers
DR. JoHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Dr. Ingelfinger,
what do we know about the specific abnormalities in the vessels
of patients with neurofibromatosis? Can one see changes in the
peculiar collagen fibers that are formed? Perhaps you could
expand on what you already have told us.
DR. INGELFINGER: The question as to whether biochemical
changes occur in or around the vasculature unique to neurofi-
bromatosis is an interesting one. It would appear that the
protein product of the NF—1 gene on chromosome l7qll.2 is
related to regulators of ras proteins [134, 135]; a portion of
NF—l that is homologous to the ras GTPase-activating protein,
that is, GAP, encodes a similar protein. It is not fully under-
stood how the abnormal gene product in neurofibromatosis
affects the vasculature. What is known is that the cellular
differentiation and expression of matrix genes in NF—l vascu-
lature can be abnormal [136], with changes in the amount of
type-IV collagen and fibronectin detected immunocytochemi-
cally. Studies do suggest that the NF cells are freely accessible
to various plasma proteins, including growth factors, which in
turn could influence the development of the lesions [136].
However, the vessels that have been examined in NF-I are
those within neurofibromas, not the renal arteries themselves.
DR. HARRINGTON: Are there any similarities between the
neurofibromata per se and the vessel lesions? Are the collagen
fibers similar, or are these totally different expressions of the
same disease?
DR. INGELFINGER: I cannot really answer this question
directly, but by deduction, I would guess that the answer may
be yes. While a small study comparing pediatric renal artery
dysplasia in patients with and without NF showed no difference
in the histologic lesions observed [17], the renovascular abnor-
malities in NF have been thought to have some neural elements.
As I mentioned earlier, a spectrum of renal vascular lesions has
long been described in neurofibromatosis, including adventitial
neurofibromas, which can cause external compression of renal
vessels or coarctation of the aorta [18, 29, 137, 138]; intimal
hyperplasia consisting of concentric intimal proliferation of
spindle cells with atrophy and thinning of media and elastica;
intimal-aneurysmal lesions with marked fibrous thickening with
irregular loss of medial smooth muscle and elastic fragmenta-
tion; lesions with fusocelluar nodules found between media and
adventitia; and epithelioid lesions. Such lesions, which have
proliferative foci or aspects have been variously considered as
having connective tissue origin, endothelial origin, or Schwann
cell origin. Vascular elements also can be abnormal. For
example, in a recent case report, smooth muscle proliferation of
spindle-shaped cells in arteries, arterioles, and veins of all
calibers throughout the renal parenchyma supported the exist-
ence of vasculopathic lesions in NF separate from lesions in
association with abnormal proliferation of cells derived from
the neural crest [18].
D. RONALD D. PERRONE (Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Several
recent studies have suggested that there is activation of the
renin-angiotensin system in autosomal dominant polycystic
kidney disease [139, 140]. Can you give us any information
about angiogenesis and polycystic kidney disease?
DR. INGELFINGER: There are not, to my knowledge, any
studies directly addressing the question of PKD and angiogen-
esis within the kidney in autosomal dominant polycystic kidney
disease (ADPKD). However, cystic renal disease is associated
with cardiovascular abnormalities [141]. Experimental steroid-
induced polycystic kidney disease induced by methylpred-
nisolone in newborn rabbits is associated with a vasculopathy in
which multiple microvascular changes, such as multiple afferent
and efferent arterioles in glomeruli, poor development of gb-
merular tufts, and persistence of sinusoidal vascular cortical
plexus, occurred [142]. These vascular changes did not corre-
late with the number or stages of cysts, and these alterations
were interpreted as a separate process [1421.
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Da. ANDREW KING (Division of Nephrology, New England
Medical Center): I'm interested in renal artery stenosis in very
young children. Is there any structural abnormality in the
kidney, such as small glomeruli? If so, when blood flow is
restored, do these children have normal growth patterns?
Finally, do either DuP 753 (losartan) or ACE inhibitors impair
renal growth in these patients?
DR. INGELFINGER: We do not know whether there are unique
structural or pathologic features within the renal parenchyma in
pediatric renovascular disease. Presumably, as in the two-
kidney, one-clip model of hypertension, the kidney ipsilateral to
a stenotic lesion is relatively protected, while the opposite side
is subject to the effects of systemic hypertension [143, 144].
Very little is known concerning the histology of pediatric
kidneys following successful repair of renal artery stenosis in a
main renal artery or branch. Whether revascularization leads to
normal or supranormal renal growth in the previously hypoper-
fused kidney is not known, although the anecdotal and undoc-
umented impression is that both renal and somatic growth
improve. More is known about segmental renal abnormalities.
For example, many children with the entity of segmental renal
hypoplasia, or Ask-Upmark kidney (which is characterized by a
dysplastic renal segment with atrophic tubules, sparse glomer-
uli, and frequently disordered vasculature) are thought to be
hypertensive [145]. Segmental hyperreninemia is often present
in the abnormal segment of an Ask-Upmark kidney, and partial
nephrectomy usually cures the hypertension [145].
I have the clinical impression that when renal artery disease
is successfully repaired in children, it can take a substantial
period of time for blood pressure to normalize, and that renal
function in such individuals may not remain normal. Like many
of you in this audience, I have followed several young people
who underwent technically successful repair of bilateral renal
artery stenosis and in whom both kidneys appeared to have
been protected from systemic hypertension, and yet in whom
long-term renal dysfunction developed insidiously, over a num-
ber of years.
You ask whether the angiotensin II receptor (AT1) antagonist
losartan (DuP 753) orconverting enzyme inhibitors impair renal
growth in children with renovascular disease. Again, the an-
swer is unclear. Experience with losartan in children is minimal
at present. However, the use of ACE inhibitors in children with
complex renovascular disease (bilateral renal artery stenosis or
renal artery stenosis in a single kidney) is associated with
decreases in renal function [116, 146, 147]. Nonetheless, many
pediatric nephrologists still use ACE inhibitors in such situa-
tions [501. To my knowledge, there are no reports about ACE
inhibitor use and renal growth in children per se. We have
observed a case in which renal perfusion and size was de-
creased while a child with multiple renal arterial stenosis
received the agent, and was improved upon discontinuation of
the agent (unreported case).
DR. RICHARD LAFAYETTE (Division of Nephrology, New
England Medical Center): Does the presence of pediatric hy-
pertension as you have defined it, greater than the 95th percen-
tile, predict essential hypertension in adults?
DR. INGELFINGER: The answer is not as clear as one would
hope. The concept of blood pressure "tracking" along the same
percentile throughout growth and development so that a child
with blood pressure at the fiftieth percentile will remain or
"track" at that level, while another at the 95th percentile will
"track" along that curve, has much epidemiologic support [1,
148, 149]. Unfortunately, tracking does not necessarily predict
essential hypertension. One of the larger available studies of
teenagers with mild or labile hypertension in which subjects
were examined 5 years later showed that about one-third had
the same blood pressure, one-third had lower blood pressure,
and another third had established hypertension [150]. Nonethe-
less, I would agree with the recommendation of the Pediatric
Task Force for following blood pressure closely in children with
a family history of essential hypertension whose blood pressure
is at the 90th to 95th percentiles [1].
DR. LAFAYETTE: Previous studies have examined the famil-
ial nature of hypertension and have found cosegregation of
certain genotypes, for example, the renin gene, with adult
hypertension. Have any similar studies been conducted in
children?
DR. INGELFINGER: In my opinion, studies in which RFLP
studies of kindreds with hypertension using candidate genes
such as the renin gene thus far have failed to show a clear
association [151, 152]. There are no specifically pediatric stud-
ies using such an approach as yet, although some of the subjects
in the RFLP studies were adolescents. It is especially exciting
that recent studies, albeit in rats, using reverse genetics [153,
154] have implicated an area on the tenth chromosome of the rat
close to or congruent with the ACE gene, which may be
associated with hypertension. Future studies examining the
analogous area in the human genome will be of great interest
and value.
Da. HARRINGTON: What is Williams syndrome? You de-
scribed it briefly in your discussion. What should we know
about it?
DR. INGELFINGER: Williams syndrome, also known as idio-
pathic hypercalcemia of infancy or the supravalvular aortic
stenosis complex, is associated with multisystem abnormalities
including multiple vascular stenoses. Williams syndrome is
characterized by a constellation of features including hypercal-
cemia in infancy; short stature; "elfin" facies; mental retarda-
tion; and stenoses of the aorta (supravalvular aortic stenosis,
coarctation), pulmonary arteries, and peripheral systemic arter-
ies [16, 155]. Since hypertension often accompanies the vascu-
lar abnormalities, physicians evaluating hypertension in chil-
dren must be aware of this syndrome. Occasionally, proteinuria
and renal functional impairment also occur in Williams syn-
drome, and we have found a higher-than-expected incidence of
single kidney [15]. The underlying abnormality accounting for
both aberrant calcium metabolism and the systemic manifesta-
tions has not been determined. Vitamin D metabolism is nor-
mal. However, calcitonin secretion may be deficient, and recent
data suggest that the calcitonin-gene-related peptide might be
responsible for some the manifestations of the syndrome [16]. It
is also worth noting the existence of an active Williams Syn-
drome Association. This group of more than 1700 members
provides information and support to patients and families, and
helps investigators learn more about the syndrome (Member-
ship, Sally Meersman, 2841 Highridge Road, LaCrescenta,
California, 91214, USA).
DR. JAMES STROM (Chief of Nephrology, St. Elizabeth's
Hospital, Brighton, Massachusetts): Would you give us the
latest estimates on the incidence in non-referred populations of
Nephrology Forum: Renovascular disease in children 501
renal artery stenosis as a cause of adolescent hypertension both
in boys and girls?
DR. INGELFINGER: It is not possible to provide accurate
incidence in unselected adolescent populations, but it is safe to
guess that the actual number is small. Most teenagers with
elevated blood pressure turn out to have mild elevation due to
essential hypertension. Among those youngsters with definable
causes of hypertension, only about 10% have renovascular
disease [2], and these individuals usually have marked hyper-
tension that is often difficult to control.
DR. AJAY SINGH (Division of Nephrology, New England
Medical Center): Are there any racial differences in the onset,
natural history, and response to treatment in pediatric patients
with essential hypertension?
DR. INGELFINGER: This is an interesting question with a
surprising answer. While hypertension is more common in
black Americans than in whites, the Second Task Force on
Blood Pressure Control in Children did not find any differences
when they pooled compatible studies to create norms for
American children [1]. Clearly there are racial influences on
variables related to blood pressure control, but the prevalence
of demonstrable hypertension does not appear to correlate with
race until adulthood [156].
In my experience, black adolescents with presumed primary
hypertension appear to respond very well to nonpharmacologic
therapy, especially salt reduction. A variety of hypotensive
agents have been used to treat primary hypertension in chil-
dren, but no racial influence has been reported.
DR. HARRINGTON: What is the role of the recently discovered
endothelial hormones, EDRF and endothelin, in renovascular
hypertension?
DR. INGELFINGER: The possible roles of endothelin and
EDRF in renovascular hypertension are only beginning to be
explored, and no data in children are yet available to my
knowledge. Experimental data from two-kidney, one-clip rats
suggest that renovascular hypertension leads to impairment of
endothelium-derived relaxing factors and sensitivity to endo-
thelin-l in resistance (mesenteric) arteries [157]. Spontaneously
hypertensive rats may have a greater renal artery vasoconstric-
tive response to endothelin than do Wistar-Kyoto rats [158].
Plasma endothelin levels in adults with atherosclerosis, includ-
ing some with renovascular lesions, appear to be elevated
compared with controls [159]. However, it will be some time
before pediatric data are available.
DR. BRIAN PEREIRA (Division of Nephrology, New England
Medical Center): Moyamoya disease in the brain is postulated
to be a consequence of arterial stenosis early in life, which leads
to a "lacy pattern" in cerebral angiograms. Is a similar pattern
observed in renal artery stenosis in infants and children?
DR. INIELFINGER: Renovascular disease in patients with
Moyamoya syndrome is increasingly reported [40, 160], but the
pattern of the renovascular lesion is not "lacy."
DR. PEREIRA: I am also interested in your comments on
Takayasu's disease. In adults, although idiopathic aortoarteritis
or "Takayasu's disease" is one of the leading causes of
renovascular hypertension in eastern populations, this disease
is uncommon in the west. Is the same distribution observed in
the pediatric population?
DR. INGELFINGER: Yes.
DR. MICHAEL LINSHAW: (Chief, Division of Pediatric Neph-
rology, New England Medical Center): If a renal artery lesion is
present in a solitary kidney that is small in size for age, would
you recommend that we repair the lesion or treat with antihy-
pertensive agents?
DR. INGELFINGER: There is no "right" answer for this
question. However, the finding of a single kidney that is smaller
than it should be suggests inadequate growth. Will correcting
the vascular lesion enhance growth? Will medical therapy delay
or prevent growth? One would need long-term data on single
kidneys in which hypertension was controlled medically or
corrected with angioplasty or surgery. No such outcome studies
are available, and any recommendation is based on individual
case reports. We do know that the use of ACE inhibition
experimentally in renovascular hypertension models prevents
renal hypertrophy [161—1631. One can control the blood pres-
sure medically in a child with renal artery stenosis in a trans-
planted or native single kidney. My experience is that renal
function in such a child often is adversely affected, at least
temporarily, by complete normalization of blood pressure. If a
renovascular lesion in a single kidney is repairable, I would
repair such a lesion if it were easily approachable.
DR. HARRINGTON: What percentage of neonates who have
umbilical catheters develop hypertension later?Have any good,
long-term studies on these children been performed?
DR. INGELFINGER: The incidence of hypertension in new-
borns ranges from 0.7% to 3.0% overall. The incidence of
neonates with umbilical artery catheters developing hyperten-
sion is low, although clinically inapparent and asymptomatic
thrombi have been detected in 24% to 91% of catheters when
angiography has been performed [31]. However, neonatal renal
artery thromboembolism is one of the most common causes of
hypertension in the neonatal period [31]. The majority of
children who suffer this complication do very well indeed, with
normalization of blood pressure and discontinuation of antihy-
pertensive medications by one year of age. Redeveloping
hypertension appears to be relatively uncommon [31, 32, 164].
Long-term followup studies on small cohorts of such infants
reveal that more than 90% appear to have no clinical problems
with hypertension. In a study by Adelman, all 10 infants who
had catheter-related thromboembolic events had normal blood
pressure an average of 5.75 years later (range ito 13 years) [32].
However, unilateral renal atrophy or abnormal radionuclide
scans are observed in the majority, so as the years go by, more
followup studies will be needed.
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